These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19543848)

  • 1. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?
    Giugliano D; Standl E; Vilsbøll T; Betteridge J; Bonadonna R; Campbell IW; Schernthaner GH; Staels B; Trichopoulou A; Farinaro E
    Acta Diabetol; 2009 Sep; 46(3):173-81. PubMed ID: 19543848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating diabetes with incretin hormones - clinical experience.
    Handelsman Y
    Pediatr Endocrinol Rev; 2008 Jun; 5(4):897-903. PubMed ID: 18552752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF
    Diabetes Educ; 2008; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
    Inzucchi SE; McGuire DK
    Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
    Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
    Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the pharmacological regimen for patients with diabetes mellitus.
    Marso SP
    Rev Cardiovasc Med; 2004; 5(3):139-47. PubMed ID: 15346097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucokinase activators in diabetes management.
    Coghlan M; Leighton B
    Expert Opin Investig Drugs; 2008 Feb; 17(2):145-67. PubMed ID: 18230050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends and new approaches in the management of diabetes mellitus.
    Kao PC; Wu TJ; Ho LL; Li XJ
    Ann Clin Lab Sci; 2000 Oct; 30(4):339-45. PubMed ID: 11045757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic approach to managing hyperglycemia for the nonendocrinologist.
    Deeg MA
    Am J Cardiol; 2005 Aug; 96(4A):37E-40E. PubMed ID: 16098842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapy in chronic kidney disease.
    Pinelli NR; Moore CL; Tomasello S
    Adv Chronic Kidney Dis; 2010 Sep; 17(5):439-49. PubMed ID: 20727514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.